New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Exclusion Criteria

• •Patients who are allergic to the study drug or drugs with similar chemical structures
• •Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception
• •Active infection
• •Active bleeding
• •Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a medical history within one year before enrollment
• •Patients with mental disorders or other conditions whereby informed consent cannot be obtained and where the requirements of the study treatment and procedures cannot be met
• •Liver function abnormalities (total bilirubin \> 1.5 times the upper limit of the normal range, ALT/AST \> 2.5 times the upper limit of the normal range or patients with liver involvement whose ALT/AST \> 1.5 times the upper limit of the normal range), or renal anomalies (serum creatinine \> 1.5 times the upper limit of the normal value)
• •Patients with a history of clinically significant QTc interval prolongation (male \> 450 ms; female \> 470 ms), ventricular heart tachycardia and atrial fibrillation, II-degree heart block, myocardial infarction attack within one year before enrollment, and congestive heart failure, and patients with coronary heart disease who have clinical symptoms and requiring drug treatment
• •Surgery on the main organs within the past six weeks
• •Drug abuse or long-term alcohol abuse that would affect the evaluation results
• •Patients who have received organ transplants (excepting bone marrow transplantation)
• •Patients not suitable for the study according to the investigator's assessment